Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 39.0 | 41 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 55.0 | 43 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 52.0 | 33 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 82.0 | 35 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 103.5 | 36 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 106.0 | 25 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 80.0 | 27 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 81.5 | 26 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 102.5 | 28 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | FGF Basic | 107.0 | 47 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 1752.0 | 34 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 149.0 | 31 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 102.0 | 33 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 29.0 | 36 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 1228.0 | 40 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 372.0 | 37 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 147.0 | 38 | |
RA2159 | TNF-a | 100 | ng/mL | 4 | FGF Basic | 169.5 | 24 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 147.0 | 37 | |
N2645 | TNF-a | 100 | ng/mL | 4 | FGF Basic | 129.0 | 35 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 4 | FGF Basic | 154.5 | 26 | |
RA2708 | TNF-a | 100 | ng/mL | 4 | FGF Basic | 138.0 | 35 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | 4 | FGF Basic | 61.0 | 35 | ||||
RA2159 | IKK16 | 2.0 | uM | 4 | FGF Basic | 55.5 | 44 | ||||
N2645 | 5z-7-oxozeaenol | 0.6 | uM | 4 | FGF Basic | 42.0 | 33 |